1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd

871.40
INR
-20.35
(-2.28%)
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
163.95
183.28
201.29
222.2
249.87
267.24
259.06
237.22
269.6
298.18
320.92
342.98
381.38
- -
Basic EPS, GAAP
16.15
20.75
23.18
29.05
37.5
43.14
32.4
35.96
48.58
53.9
58.86
72.65
78.71
- -
Free Cash Flow per Basic Share
22.52
16.98
11.37
20.6
34.28
23.06
22.8
39.9
13.55
32.74
12.62
18.56
29.01
- -
Dividend per Share
5.1
6.3
7.2
-0.4
14.41
3.18
18.7
- -
10.2
12.05
14.32
15.36
17.99
- -
Book Value per Share
58.73
71.92
87.58
117.09
133.48
168.79
174.32
214.55
255.77
277.32
328.42
389.23
446.47
- -
Tangible Book Value per Share
58.69
71.87
87.23
116.81
133.22
168.44
172.49
213.5
255.1
276.9
327.54
388.71
445.92
- -
Basic Weighted Avg Shares
5
5
5
5
5
5
5
5
5
5
4
4
4
4
Sales/Revenue/Turnover
762
852
936
1,033
1,147
1,226
1,189
1,089
1,237
1,361
1,416
1,514
1,683
- -
Operating Margin (%)
13.07
14.78
15.46
17.39
19.62
19.26
14.67
16.36
20.49
20.65
21.73
24.89
24.14
- -
Depreciation Expense
16
27
20
18
15
14
23
20
19
23
23
27
31
- -
Net Income, GAAP
75
96
108
135
172
198
149
165
223
246
260
321
347
- -
Effective Tax Rate (%)
27.33
32.71
35.95
34.04
31.88
25.67
29.65
23.75
25.35
25.13
26.15
27.02
25.33
- -
Profit Margin (%)
9.85
11.32
11.52
13.08
15.01
16.14
12.51
15.16
18.02
18.07
18.34
21.18
20.64
- -
Working Capital
169
250
309
456
529
671
697
620
546
653
933
377
719
- -
LT Debt
- -
- -
2
2
2
- -
14
9
5
- -
- -
15
18
- -
Total Equity
273
334
407
544
613
775
800
985
1,174
1,224
1,449
1,718
1,970
- -
Return on Invested Capital (%)
25.65
24.49
21.49
22.23
24.82
23.95
14.4
14.36
16.83
17.04
16.91
17.3
15.41
- -
Return on Capital (%)
27.42
28.47
25.51
25.68
28.52
27.4
17.89
17.83
19.82
19.91
19.35
20.17
18.66
- -
Return on Common Equity (%)
30.05
31.77
29.07
28.39
29.75
28.54
18.89
18.49
20.66
20.53
19.43
20.25
18.84
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
6
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
18
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
- -
- -
- -

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
951
- -
Cash, Cash Equivalents & STI
- -
473
- -
Accounts Receivable, Net
- -
244
- -
Inventories
- -
136
- -
Total Current Liabilities
- -
231
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.42%
15.03%
14.71%
Free Cash Flow
30.15%
23.01%
56.3%
Net Income, GAAP
13.67%
16.56%
8.34%
Sales/Revenue/Turnover
6.26%
9.16%
11.2%
Total Cash Common Dividend
- -
- -
17.09%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
325
412
369
410
1,514
2026
355
- -
430
446
1,683
2027
355
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.8
21.75
14.75
19.34
72.65
2026
17.66
- -
13.44
24.58
78.71
2027
13.34
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
15.36
2026
- -
- -
- -
- -
17.99
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ashish Uttam Bhuta
Full Time Employees
801
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Nirmala Apartments Mumbai MA India 400058
IPO Date
Oct 18, 1994
Website
jenburkt.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations and healthcare products in India and internationally across 13 countries. Founded in 1985 and headquartered in Mumbai, India, the company offers a broad portfolio of prescription and over-the-counter drugs spanning therapeutic areas including anti-fungals, anti-ulcerants and antacids, aphrodisiacs, anti-malarials, anthelmintics, anti-diabetics, pain management, analgesics and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain treatments, anti-arthritics, anti-infectives, cough and cold remedies, dermatological products, and consumer healthcare items; key brands include Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega, Nervijen P, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zixa, and Zydol Suspension. The company operates a WHO-GMP approved manufacturing plant in Sihor, Gujarat, supported by an R&D unit approved by the Ministry of Science and Technology, Government of India, and serves government institutions, hospitals, pharmacies, and over 100,000 doctors through more than 1,000 stockists and 400,000 pharmacies globally. In recent developments, Jenburkt Pharmaceuticals reports consistent revenue and profit growth, with net profit rising 5.83% to Rs 10.16 crore and sales up 10.53% to Rs 45.56 crore in the quarter ended September 2025; the company also launched a new over-the-counter division, Jenburkt Wellness, in fiscal year 2021-22 to expand into physical wellness products, increased its final dividend to Rs 18 per share in 2025, and maintains steady institutional holdings while adopting technologies like SAP S4 HANA for operational efficiency.